CN118436766B - 一种大鲵肽组合物及制备方法和应用 - Google Patents
一种大鲵肽组合物及制备方法和应用 Download PDFInfo
- Publication number
- CN118436766B CN118436766B CN202410903055.7A CN202410903055A CN118436766B CN 118436766 B CN118436766 B CN 118436766B CN 202410903055 A CN202410903055 A CN 202410903055A CN 118436766 B CN118436766 B CN 118436766B
- Authority
- CN
- China
- Prior art keywords
- giant salamander
- salamander peptide
- extract
- peptide composition
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000157862 Dicamptodontidae Species 0.000 title claims abstract description 71
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000000284 extract Substances 0.000 claims abstract description 26
- 230000036039 immunity Effects 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 22
- 229960003080 taurine Drugs 0.000 claims abstract description 20
- 230000002708 enhancing effect Effects 0.000 claims abstract description 19
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 10
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 10
- 235000021119 whey protein Nutrition 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 241000005787 Cistanche Species 0.000 claims description 21
- 241000208340 Araliaceae Species 0.000 claims description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 14
- 235000008434 ginseng Nutrition 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 13
- 235000020710 ginseng extract Nutrition 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 9
- 235000013372 meat Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000005238 degreasing Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 4
- 108090000145 Bacillolysin Proteins 0.000 claims description 2
- 102000035092 Neutral proteases Human genes 0.000 claims description 2
- 108091005507 Neutral proteases Proteins 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 10
- 244000005700 microbiome Species 0.000 abstract description 7
- 241000196324 Embryophyta Species 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 241000269333 Caudata Species 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 34
- 230000000694 effects Effects 0.000 description 34
- 229920002527 Glycogen Polymers 0.000 description 12
- 229940096919 glycogen Drugs 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 12
- 230000009182 swimming Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 241000336291 Cistanche deserticola Species 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000242 pagocytic effect Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002929 anti-fatigue Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000413 hydrolysate Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229940001941 soy protein Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000336316 Cistanche tubulosa Species 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种大鲵肽组合物及制备方法和应用,组合物包括植物提取物‑人参提取物、动物提取物‑大鲵肽粉和微生物提取物‑肉苁蓉提取物、牛磺酸和乳清蛋白。该组合物包含植物界、动物界、微生物界来源的成分,有助于缓解体力疲劳,并能够增强免疫力;且该组合物生物利用度高、口感佳,安全性高,能够用于制备缓解体力疲劳、增强免疫力的药物或保健食品。
Description
技术领域
本发明属于保健食品技术领域,尤其是涉及一种大鲵肽组合物及制备方法和应用。
背景技术
随着现代社会生活节奏的加快和工作压力的增大,越来越多的人面临着疲劳和免疫力下降的问题。市场上现有的抗疲劳和增强免疫力产品存在诸多不足,如效果不明显、副作用较大等。因此,开发一种安全、有效且具有广泛应用前景的抗疲劳、增强免疫力组合物具有重要意义。
近年来,国内外在抗疲劳和增强免疫力领域的研究取得了一定进展,但仍存在许多尚未解决的问题。例如,已知的一些活性成分虽然具有一定的抗疲劳和增强免疫力作用,但其效果有限且可能存在一定的副作用。此外,现有产品的配方设计和制备工艺也存在一定的局限性,难以满足市场的需求。
发明内容
为解决上述技术问题,本发明提供一种大鲵肽组合物及制备方法和应用。
本发明采用的技术方案是:一种大鲵肽组合物,包括大鲵肽粉3~20份,肉苁蓉提取物5~30份,人参提取物5~30份,牛磺酸1~5份和乳清蛋白1~5份。
优选地,包括大鲵肽粉3~10份,肉苁蓉提取物10~20份,人参提取物10~20份,牛磺酸2~4份和乳清蛋白2~4份。
大鲵肽组合物的制备方法,将大鲵肽粉、肉苁蓉提取物、人参提取物、牛磺酸和乳清蛋白混合,得到大鲵肽组合物。
优选地,取新鲜大鲵肉,脱脂处理,加水匀浆,加入蛋白酶进行酶解,过滤获得大鲵肽酶解液,浓缩冻干得到大鲵肽粉。
优选地,对人参热回流提取,提取液冷冻干燥得到人参提取物。
优选地,对肉苁蓉热回流提取,提取液冷冻干燥得到肉苁蓉提取物。
大鲵肽组合物在制备缓解体力疲劳、增强免疫力药物、食品或制剂中的应用。
优选地,将大鲵肽组合物制成药物剂型或食品形态;
或者,将大鲵肽组合物与其他食品辅料或药物辅料混合,制成食品形态或药物剂型;
本发明具有的优点和积极效果是:提供一种包含植物界、动物界、微生物界来源的成分,增加牛磺酸,以补充能量,改善疲劳。牛磺酸还被用于增强免疫力,重新激活耗竭的CD8+T细胞,并提高癌症治疗效果。制备得到的大鲵肽组合物具有显著的缓解体力疲劳、增强免疫力效果;且该组合物生物利用度高、口感佳,安全性高。
本专利技术提出了一种新型的缓解体力疲劳、增强免疫力组合物,其创新点在于采用了新的活性成分和独特的配方设计。通过优化成分配比和制备工艺,本发明能够显著提高产品的功效和安全性,有效解决现有技术存在的问题。
本专利技术的应用前景广阔,可以广泛应用于保健品、药品等领域。随着人们对缓解体力疲劳和增强免疫力需求的不断增加,该产品有望在市场上取得良好的经济效益和社会效益。
综上所述,本专利技术提供了一种安全、有效且具有广泛应用前景的缓解体力疲劳、增强免疫力组合物,为解决现有技术存在的问题提供了新的思路和方法。
附图说明
图1PPPSM对小鼠游泳时间、糖原含量的影响;A.PPPSM对小鼠游泳时间的影响;B.PPPSM对小鼠肝糖原含量的影响;C.PPPSM对小鼠肌糖原含量的影响;(*P<0.05vs空白组);
图2 PPPSM 对小鼠体重、体重增重的影响;A.PPPSM 对小鼠体重的影响;B. PPPSM对小鼠体重增重的影响;
图3 PPPSM对小鼠脏器指数的影响;A.PPPSM对小鼠脾脏指数的影响;B.PPPSM对小鼠胸腺指数的影响;C.PPPSM对小鼠肝脏指数的影响。(*P<0.05,**P<0.01vs空白组);
图4PPPSM对小鼠碳廓清指数、吞噬指数的影响;A.PPPSM对小鼠碳廓清指数的影响;B.PPPSM对小鼠吞噬指数的影响。*P<0.05,**P<0.01vs空白组;
图5 PPPSM 对小鼠脾淋巴细胞转化能力的影响 *P<0.05 vs 空白组。
具体实施方式
下面结合附图对本发明的实施例做出说明。
本发明涉及一种大鲵肽组合物及制备方法和应用,由植物提取物-人参提取物、动物提取物-大鲵肽粉、微生物提取物-肉苁蓉提取物、以及牛磺酸配伍制备而成,该组合物包含植物界、动物界、微生物界来源的成分,具有显著的缓解体力疲劳、增强免疫力效果;且该组合物生物利用度高、口感佳,安全性高。
大鲵肽组合物中包括大鲵肽粉3~20份,肉苁蓉提取物5~30份、人参提取物5~30份,牛磺酸1~5份和乳清蛋白1~5份。制备时分别制备得到大鲵肽粉、肉苁蓉提取物和人参提取物,再取牛磺酸和乳清蛋白,按照配方称取各原料,添加食品辅料或是药学上可接受的辅料后,混合均匀按照本领域常规的工艺制备成相应的剂型或是食品形态。制备得到的大鲵肽组合物能够用于制备预防或缓解疲劳、增强免疫力的药物或保健食品。
大鲵是现存体形最大的两栖类动物,在3亿多年进化史中大鲵生理特性并未发生较大变化,仍然保留着古老许多特性,是地球生物进化的“活化石”,被称为“水中人参”。大鲵机体中含有70多种天然活性物质,这些活性物质它能促进人体生理活性,改善人体细胞代谢水平,促进人体蛋白质合成,提高人体免疫功能,增强人体抗病能力,延缓衰老,对贫血、痢疾、癫痫等病症都有显著疗效,还具有补肾、强壮、补血益气的功效。大鲵肽分子量分布在 100~3000 Da 含量约为 95%,多为分子量较小的短肽,易于被人体吸收。大鲵肽中,蛋白含量高达 87.6 g/100 g,必须氨基酸含量为 44.65%。研究证明,补充生理活性肽能提高运动员的体重、运动肌肉的力量和血清 Ca2+ 含量,抑制或者减少因运动而引起的蛋白质损耗,维持或者促进体内正常蛋白质的合成,减轻或者延缓由运动引起的运动功能降低,从而达到缓解体力疲劳的作用。大鲵肽不但为人体提供组建肌肉蛋白质需要的各种氨基酸,同时支链氨基酸可作为能源物质通过氧化作用为人体运动提供需要的能量、还能发挥维持内环境渗透压、酸碱度等的稳态功能。此外大鲵肽最大的特点是具有极强的生理活性、结构和功能多样性,是其他营养手段缓解体力疲劳、增强免疫力无法比拟的。
肉苁蓉(CistanchedeserticolaY.C.Ma)属多年生寄生草本植物。别名苁蓉、地精、疆芸、大芸、寸芸或金笋等。具有提高免疫力、抗衰老、改善阳痿早泄、缓解体力疲劳、保护肝脏、保护心脑血管、润肠排毒等作用。药用价值极高,是我国传统的名贵中药材,俗称“沙漠人参”。肉苁蓉能明显延长肾阳虚小鼠游泳时间,具有增强耐力、缓解体力疲劳作用;肉苁蓉能增加运动小鼠血红蛋白含量,减少乳酸生成,加速疲劳消除。复方管花肉苁蓉能明显延长小鼠负重游泳时间,降低乳酸水平,降低负荷运动后小鼠血清CK水平,具有缓解疲劳作用。
人参,学名为Panax ginseng C.A.Mey,属于五加科植物,其主要有效成分为人参皂苷,这是一种具有多种药理作用的化合物,包括缓解体力疲劳、抗衰老、提高免疫力、调节内分泌等。人参的这些功效使其在中医药中被广泛应用,主要用于补气养血、生津止渴、安神益智等。在现代研究中,人参被发现有抗休克、强心、降血压、抗缺氧和保护心肌的作用,能改善血液流变学和抗血栓形成。它还具有兴奋垂体-肾上腺皮质系统、抗应激、提高免疫功能、增强造血功能,并能调节中枢神经系统兴奋与抑制过程,促进学习记忆和缓解体力疲劳作用。
牛磺酸(Taurine),是一种由含硫氨基酸转化而来的氨基酸,广泛分布于体内各个组织和器官,主要以游离状态存在于组织间液和细胞内液中,因最先于牛胆汁中发现而得名。常见的功能饮料中就添加有牛磺酸,以补充能量,改善疲劳。牛磺酸还被用于增强免疫力,补充牛磺酸可以重新激活耗竭的CD8+T细胞,并提高癌症治疗效果。
以上原料联合使用,充分挖掘原料的营养和功效价值,利用动物、植物和微生物不同来源的原料组合更好满足人体对营养成分均衡补充的需求;组合物原料分别来源于植物、动物、微生物三界,都是增强免疫力极佳的原料,组合一起具有协同增效的作用,可以从不同方面发挥作用,缓解体力疲劳、增强免疫力效果。在保证缓解体力疲劳、增强免疫力效果的同时,该组合可以最大限度地保证多方面兼顾,从而增加了组合物的应用范围。
下面结合附图对本发明方案做出说明,其中,未具体说明操作步骤的实验方法,均按照相应商品说明书进行,实施例中所用到的仪器、试剂、耗材如无特殊说明,均可从商业公司购买得到。
实施例1:大鲵肽组合物的制备
1.1大鲵肽粉的制备
1原料预处理
取新鲜大鲵肉,将鱼皮、鱼肉、鱼油等清晰地剥离开,洗净,臭氧水中消毒灭菌约半小时,将其剪碎成0.5cm×0.5cm×0.5cm大小的肉丁,称量湿重。
2脱脂
按照料液质量比1:2加入98%异丙醇,然后置于37℃温水浴中脱脂1h,每隔10min用玻璃棒轻轻搅拌。然后3000r/min离心10min,弃上清,按料液质量比1:1加入98%异丙醇,继续置于水浴中脱脂,离心弃上清,得到脱脂的大鲵肉。
3加水匀浆
依照优化后的料液质量比加水,并用玻璃棒均匀搅拌。
4酶解
在中性蛋白酶浓度2000IU/g、料液比为1:8、加酶量为0.1%、温度50℃、pH6~7的条件下连续进行酶解,持续反应3h,升温至80-100℃灭酶5-10min,过滤即可得到大鲵肉蛋白肽水解液。
5浓缩干燥
将水解液浓缩冷冻干燥,得大鲵肽冻干粉。
1.2肉苁蓉提取物的制备
将肉苁蓉加热回流提取或超声提取1~3次,每次加入基于药材总重量的1~20倍量的水或是浓度为10%~95%的乙醇水溶液,每次提取1~3小时,过滤,滤液合并;
将所述滤液浓缩,冷冻干燥,即得肉苁蓉提取物。
1.3人参提取物的制备
将人参加热回流提取或超声提取1~3次,每次加入基于药材总重量的1~20倍量的水或是浓度为10%~95%的乙醇水溶液,每次提取1~3小时,过滤,滤液合并;将所述滤液浓缩,冷冻干燥,即得人参提取物。
1.4大鲵肽组合物的制备
分别取大鲵肽粉10份,肉苁蓉提取物15份,人参提取物15份,牛磺酸1份,乳清蛋白3份,混匀后得到大鲵肽组合物(Prescription Peptide Powder of Salamander’s Meat,PPPSM)。
实施例2:大鲵肽组合物缓解疲劳功效研究
2.1分组称重
健康KM小鼠48只,体重20±2g,雌雄各半,分成空白对照组、阳性对照组、人参组、大鲵组、肉苁蓉组、PPPSM不同剂量组,每组六只,雌雄各3只,分开饲养,称重记录。
2.2剂量选择
阳性对照组选择大豆分离蛋白粉(Isolated Soy Protein Powder, ISPP):根据能够缓解生理性疲劳和增强免疫力的蛋白类保健食品的组成情况分析可知,大豆分离蛋白粉常常是该类产品配伍中的主要原料,对于该类功效的发挥有着较为重要的作用。本实施例将其与大鲵肽组合物(PPPSM)作对比功效评价,一般人体每日推荐服用量为10g。按照人体每日服用剂量的5、10和15倍设定1g/kg·d、2g/kg·d和3g/kg·dPPPSM、2g/kg·d人参组、2g/kg·d肉苁蓉组、2g/kg·d大鲵6个剂量组。
2.3灌胃给药
PPPSM三个剂量组和三个单味给药组,分别按照设定剂量给药,阳性对照组按照3g/kg·d灌胃ISPP,根据小鼠体重灌胃0.2ml/20g,空白对照组灌胃生理盐水,每日一次,连续30天。
2.4游泳实验
末次灌胃30min后,迅速提起鼠尾,将小白鼠放入水池中(水深不少于30cm,水温25℃左右)中游泳,观察各实验组小白鼠游泳情况,并准确记录下自游泳开始至死亡的时间,即为小白鼠游泳时间,详见表1和图1。
由表1和图1A可知,ISPP组、三个单味给药组和三个PPPSM组小鼠的游泳时间均长于空白组,证明ISPP、三个单味给药组和PPPSM均能够提高小鼠耐力,比对ISPP组、三个单味给药组和三个PPPSM组能够看出,2g/kg·d的PPPSM添加量效果更为突出,与空白组比较,2g/kg·dPPPSM组的小鼠游泳时间显著延长(P<0.05),对小鼠耐力的提高具有突出作用。
表1PPPSM对小鼠游泳时间、糖原含量的影响结果分析表(x±s,n=6)
*P<0.05 vs 空白组
2.5糖原含量的测定
将死亡小鼠置于于冰板上取新鲜肝脏、后腿肌肉组织,并用冰冷生理盐水冲洗干净后滤纸吸干,称重,所取组织重量均小于100mg。按照糖原试剂盒的要求检测小鼠的糖原。检测结果如表1和图1所示。
由表1可知,与空白组比较,ISPP组、三个单味给药组和三个PPPSM组均能够提高肝糖原含量,其中,又以3g/kg·d的PPPSM组别提高量最大,相对于空白组3g/kg·dPPPSM组的肝糖原含量显著升高(P<0.05),如图1B所示;说明1g/kg·d、2g/kg·d、3g/kg·d的PPPSM供给,均能够提高小鼠机体供能。
比较5个组别肌糖原含量,ISPP组、三个单味给药组和三个PPPSM组相对于空白组,在肌糖原含量上也均具有提高,与空白组比较,2g/kg·d、3g/kg·dPPPSM组的肌糖原含量显著升高(P<0.05),如图1C所示,表明2g/kg·d、3g/kg·d的PPPSM均能够显著升高小鼠肌糖原含量,提高机体供能。
实施例3:大鲵肽组合物改善伴随症状(免疫力低下)的功效研究
3.1分组称重
健康KM小鼠60只,体重20±2g,雌雄各半,分成两个大组。每个大组分成空白对照组、阳性对照组、PPPSM不同剂量组,每个剂量组六只,雌雄各3只,分开饲养,称重记录。
3.2剂量选择
阳性对照组选择大豆分离蛋白粉(ISPP):实验组PPPSM设定1g/kg·d、2g/kg·d和3g/kg·dPPPSM三个剂量组,另设置2g/kg.d三个单味给药组共六组。
3.3灌胃给药
PPPSM三个剂量组,三个单味给药组,分别按照设定剂量给药,阳性对照组按照3g/kg·d灌胃ISPP,根据小鼠体重灌胃0.2ml/20g,空白对照组灌胃生理盐水,每日一次,连续30天。
3.4碳廓清实验
末次给药前,对第一大组的小鼠进行二次称重记录,之后末次给药。给药后1h,尾静脉注射20%的碳素墨水(0.05ml/10g)。分别2、12分钟眼眶取血20µL,加到含2mL0.1%Na2CO3溶液EP管中摇匀。处死小鼠,无菌取脾脏、胸腺、肝脏,称重,计算体增、脏器指数。结果如表2和图2-图3所示。
表2 PPPSM对小鼠体重、脏器指数的影响结果分析表(x±s,n=6)
*p<0.05.**P<0.01 vs 空白组
根据表2数据比对各实验组小鼠体重数值与增重数值,与空白组比较,各组体重后增重均没有显著差异(P>0.05)(见图2),说明PPPSM、三个单味药组和ISPP对体重增重均没有明显影响。比较脾脏指数,与空白组比较,3g/kg·dPPPSM组的脾脏指数显著升高(P<0.05)(见图3A),说明3g/kg·d的PPPSM能够显著升高小鼠脾脏指数。比较胸腺指数,与空白组比较,1g/kg·d、2g/kg·d和3g/kg·dPPPSM组的胸腺指数均显著升高(P<0.05)(见图3B),说明1g/kg·d、2g/kg·d和3g/kg·d的PPPSM均能够显著升高胸腺指数。比较肝脏指数,与空白组比较,3g/kg·d的PPPSM组的肝脏指数和ISPP组的肝脏指数均有显著差异(P<0.05)(见图3C),说明3g/kg·d的PPPSM和ISPP组对小鼠肝脏指数均有明显影响。
用分光光度计(680 nm)测定吸光度(OD2 和 OD12),计算碳廓清指数 K 和吞噬指数α。
K=(lgOD2-lgOD12)/(t2-t1)
吞噬指数α=体质量× /肝脾重
检测和计算结果如表3和图4所示。
表3 PPPSM 对小鼠吞噬指数和淋巴细胞转化指数的影响结果分析表(x±s, n=6 )
*P<0.05,**P<0.01 vs 空白组
由表3可知,ISPP组、三个单味药组和三个PPPSM组在碳廓清指数上均能够有所提高,与空白组比较,3g/kg·dPPPSM组的碳廓清指数显著升高(P<0.05)(见图4A),再比较吞噬指数,与空白组比较,2g/kg·d和3g/kg·dPPPSM组的吞噬指数均显著升高(P<0.05)(见图4B),说明2g/kg·d和3g/kg·d的PPPSM均能够显著升高小鼠吞噬指数,显著增强小鼠非特异性免疫功能。
3.5脾淋巴细胞转化实验
脾细胞悬液的制备:第二大组末次给药后,脱颈椎处死,酒精消毒。无菌条件下取脾脏,置于预冷的PBS中,分别剪碎脾脏,吸取上清,1000r/min离心5min。弃上清液,用1mL无菌水重悬,30s后加入1.7%NaCl溶液调至等渗。同样条件下离心取上清,细胞沉淀加适量1640得单细胞悬液。计数调整细胞浓度为5×106个/mL。
MTT测量:将悬液加入96孔板中,实验孔加10μL50μg/mLConA,对照孔加等量培养基,重复3孔,培养48h,弃上清,每孔加100μL1mg/mLMTT,继续培养2-6h,每孔加100μL酸性异丙醇,培养箱过夜后,用酶标仪测各孔OD值(570nm),计算转化指数。结果如表3和图5所示
由表3可知,与空白组比较,各实验组的脾淋巴细胞转化指数均显著升高(P<0.05)(见图5),说明不同原料组和大鲵肽组合物均能够提高小鼠脾淋巴细胞转化能力,显著增强特异性免疫功能。
实施例4:一种大鲵肽组合物的固体饮料
分别取大鲵肽粉10份,肉苁蓉提取物10份,人参提取物10份,牛磺酸1份,乳清蛋白5份。
将各原料混合均匀粉碎过60目筛,分装3g每袋,即得大鲵肽组合物固体饮料。
实施例5:一种大鲵肽组合物的压片糖果
分别称取大鲵肽粉8份,肉苁蓉提取物10份,人参提取物6份,牛磺酸1份,微晶纤维素30份,木糖醇30份,柠檬酸4份,硬脂酸镁2份,糊精浆10份。
按配方将大鲵肽粉、肉苁蓉提取物、人参提取物、牛磺酸、微晶纤维素、木糖醇、柠檬酸混合均匀,加入适量的糊精浆搅拌,搅拌至握之成团,按之即散的软材,再用16目筛制粒,干燥,过20目筛整粒,添加硬脂酸镁混合均匀后压片。即得大鲵肽组合物的压片糖果。
以上对本发明的实施例进行了详细说明,但所述内容仅为本发明的较佳实施例,不能被认为用于限定本发明的实施范围。凡依本发明申请范围所作的均等变化与改进等,均应仍归属于本发明的专利涵盖范围之内。
Claims (8)
1.一种大鲵肽组合物,其特征在于:由大鲵肽粉10份,肉苁蓉提取物15份,人参提取物15份,牛磺酸1份和乳清蛋白3份组成。
2.权利要求1所述的大鲵肽组合物的制备方法,其特征在于:将大鲵肽粉、肉苁蓉提取物、人参提取物、牛磺酸和乳清蛋白混合,得到大鲵肽组合物。
3.根据权利要求2所述的大鲵肽组合物的制备方法,其特征在于:取新鲜大鲵肉,脱脂处理,加水匀浆,加入中性蛋白酶进行酶解,过滤获得大鲵肽酶解液,浓缩冻干得到大鲵肽粉。
4.根据权利要求2所述的大鲵肽组合物的制备方法,其特征在于:对人参热回流提取,提取液冷冻干燥得到人参提取物。
5.根据权利要求2所述的大鲵肽组合物的制备方法,其特征在于:对肉苁蓉热回流提取,提取液冷冻干燥得到肉苁蓉提取物。
6.权利要求1所述的大鲵肽组合物在制备缓解体力疲劳、增强免疫力的药物或食品中的应用。
7.根据权利要求6所述的应用,其特征在于:将大鲵肽组合物制成药物剂型或食品形态。
8.根据权利要求6所述的应用,其特征在于:将大鲵肽组合物与其他食品辅料或药物辅料混合,制成食品形态或药物剂型。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410903055.7A CN118436766B (zh) | 2024-07-08 | 2024-07-08 | 一种大鲵肽组合物及制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410903055.7A CN118436766B (zh) | 2024-07-08 | 2024-07-08 | 一种大鲵肽组合物及制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118436766A CN118436766A (zh) | 2024-08-06 |
| CN118436766B true CN118436766B (zh) | 2024-09-17 |
Family
ID=92330501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410903055.7A Active CN118436766B (zh) | 2024-07-08 | 2024-07-08 | 一种大鲵肽组合物及制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118436766B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119678999A (zh) * | 2024-12-20 | 2025-03-25 | 广东润和生物科技有限公司 | 一种有助于抗氧化、缓解体力疲劳的蛋白奶昔及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178932A (zh) * | 2011-04-20 | 2011-09-14 | 威海博力生物工程有限公司 | 一种缓解人体疲劳、增强免疫力的制剂 |
| CN107661455A (zh) * | 2017-11-15 | 2018-02-06 | 朱勇 | 一种补肾壮阳提高性能力的药物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108420854B (zh) * | 2017-02-13 | 2021-01-19 | 杏辉天力(杭州)药业有限公司 | 提高耐力表现的抗疲劳组合物 |
| CN108402373A (zh) * | 2018-04-23 | 2018-08-17 | 深圳市炜鑫生物科技有限公司 | 一种补阳保健食品及其制备方法 |
| CN110584129A (zh) * | 2019-10-18 | 2019-12-20 | 成都鲵肽生物科技有限公司 | 一种用于肿瘤康复大鲵多肽粉组合物 |
| CN113057334A (zh) * | 2021-04-13 | 2021-07-02 | 湖南鲵康生物科技有限公司 | 一种具有益脑作用的大鲵复合蛋白粉组合物及其制备方法 |
-
2024
- 2024-07-08 CN CN202410903055.7A patent/CN118436766B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178932A (zh) * | 2011-04-20 | 2011-09-14 | 威海博力生物工程有限公司 | 一种缓解人体疲劳、增强免疫力的制剂 |
| CN107661455A (zh) * | 2017-11-15 | 2018-02-06 | 朱勇 | 一种补肾壮阳提高性能力的药物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118436766A (zh) | 2024-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101574140B (zh) | 一种具有增强人体免疫功能和抗疲劳作用的饮品组合物 | |
| CN101624570B (zh) | 中药培养养殖肉灵芝方法及养殖肉灵芝保健品的制备方法 | |
| CN102907604B (zh) | 一种降糖、降压、减肥、通便养颜、抗疲劳保健品及其生产工艺 | |
| CN102048210B (zh) | 一种具有缓解疲劳功能的红枣保健饮料 | |
| CN102100805B (zh) | 一种具有缓解体力疲劳及增强免疫功能的组合物及其制备方法和用途 | |
| CN107259575A (zh) | 一种具有抗氧化功能的保健酵素及其制备方法 | |
| CN103027138B (zh) | 一种醒脾茶及其制作方法 | |
| CN108420854B (zh) | 提高耐力表现的抗疲劳组合物 | |
| CN102526698A (zh) | 虫草多肽氨基酸营养液 | |
| CN105686006A (zh) | 一种牡蛎复合功能食品及其制备方法 | |
| CN106072527A (zh) | 一种排毒养颜的纳豆组方及其制备方法 | |
| CN118436766B (zh) | 一种大鲵肽组合物及制备方法和应用 | |
| CN102763873A (zh) | 天麻营养饮料及其生产工艺 | |
| CN103405577B (zh) | 一种增强免疫力、缓解疲劳的药用组合物 | |
| CN106244371A (zh) | 一种降血糖黄精葡萄保健酒及其生产工艺 | |
| CN108740863A (zh) | 一种益气补血的组合物及其制备方法和应用 | |
| CN107164446A (zh) | 鹿血肽的制备方法及其抗疲劳作用 | |
| CN105029400A (zh) | 类风湿关节炎医学配方食品 | |
| CN106987512A (zh) | 一种保健酒及其制备方法 | |
| CN103877122A (zh) | 中药阿胶原料的生产方法及其产品 | |
| CN104187637A (zh) | 壮阳全营养配方食品 | |
| CN109315774A (zh) | 一种枸杞黄芪保健食品及其制备方法 | |
| RU2147239C1 (ru) | Общеукрепляющее неспецифическое иммуномодулирующее средство | |
| CN106723048A (zh) | 一种用于缓解疲劳的保健食品及其制备方法 | |
| CN104906140A (zh) | 一种阿胶及其制备方法与相关设备 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |